|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 950 F Street, NW |
Address2 | Suite 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31350-12
|
||||||||
|
6. House ID# 306540000
|
TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul J. Larsen, Deputy Compliance Officer & Assistant General Counsel |
Date | 07/20/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 1, Full-Year Continuing Appropriations Act, 2011: Provisions relating to FDA, BARDA, Patents, USTR and NIH
H.R. 1473, Department of Defense and Full-Year Continuing Appropriations Act, 2011: Provisions relating to FDA, BARDA, Patents, USTR and NIH
H.R. 2017, Department of Homeland Security Appropriations Act, 2012: Provisions relating to Customs and Border Protection
H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012: FDA related provisions
H.R. 2219, Department of Defense Appropriations Act, 2012: Provisions relating to various health accounts
FY 2012 Budget Resolution: Budget for Federal agencies and programs and related authorizations and tax proposals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mike |
Anway |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Andrea |
Douglas |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Valerie |
Jewett |
|
|
|
Kimberly |
Love |
|
|
|
Brian |
Nagle |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Matt |
Sulkala |
|
|
|
Hallie |
Maranchick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 243, Patent Lawsuit Reform Act of 2011: Provisions related to false patent marking
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provision related to authorized generics
H.R. 1056, Patent Continuing Disclosure Act: Provisions related to false patent marking
H.R. 1249, America Invents Act: Provisions related to patent reform
H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives
S. 23, America Invents Act: Provisions related to patent reform
S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements
S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics
International intellectual property issues
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
John |
Castellani |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Valerie |
Jewett |
|
|
|
David |
Korn |
|
|
|
Brian |
Nagle |
|
|
|
Anne |
Pritchett |
|
|
|
Matt |
Sulkala |
|
|
|
Cara |
Moon |
|
Staff Asst. and Leg. Correspondent - Rep. John |
|
" |
" |
|
Shadegg; Leg. Asst. - Rep. Bobby Jindal; Senior |
|
" |
" |
|
Leg. Asst. and Leg. Dir. - Rep. Marsha |
|
" |
" |
|
Blackburn |
|
Hallie |
Maranchick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 5, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011: Provisions related to FDA and product liability
H.R. 1065, Pill Mill Crackdown Act of 2011: Provisions related to prescription drug abuse
H.R. 1266, Fraudulent Prescription Prevention Act of 2011: Provisions related to prescription drug abuse
H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives
H.R. 2119, Ryan Creedon Act of 2011: Provisions related to drug diversion
H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011: Provisions related to prescription drug shortages
S. 218, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011: Provisions related to FDA and product liability
S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011: Provisions related to importation
S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011: Provisions related to prescription drug abuse
Health care reform implementation issues, including health reform fee and essential benefits
General FDA advocacy
User fee reauthorization
Anti-counterfeiting issues
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA), Executive Office of the President (EOP), Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mike |
Anway |
|
|
|
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Andrea |
Douglas |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Gregory |
Gierer |
|
|
|
Ann |
Kaplan |
|
|
|
Kimberly |
Love |
|
|
|
Kendra |
Martello |
|
|
|
Brian |
Nagle |
|
|
|
Anne |
Pritchett |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Matt |
Sulkala |
|
|
|
Cara |
Moon |
|
Staff Asst. and Leg. Correspondent - Rep. John |
|
" |
" |
|
Shadegg; Leg. Asst. - Rep. Bobby Jindal; Senior |
|
" |
" |
|
Leg. Asst. and Leg. Dir. - Rep. Marsha |
|
" |
" |
|
Blackburn |
|
Hallie |
Maranchick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 452, Medicare Decisions Accountability Act of 2011: Provisions related to Independent Payment Advisory Board (IPAB)
H.R. 675, Strengthening Medicare Anti-Fraud Measures Act of 2010: Provisions related to exclusion issues
H.R. 999, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues
H.R. 2190 Medicare Drug Savings Act of 2011: Provisions related to Part D issues
H.R. 2248, Medicare Prescription Drug Price Negotiation Act of 2011: Provisions related to Part D non-interference issues
S. 31, Prescription Drug and Health Improvement Act of 2011: Provisions related to Part D non-interference provisions
S. 44, Medicare Prescription Drug Price Negotiation Act of 2011: Provisions related to Part D issues
S. 454, Strengthening Program Integrity and Accountability in Health Care Act of 2011: Provisions related to exclusion issues
S. 560, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues
S. 668, Health Care Bureaucrats Elimination Act: Provisions related to Independent Payment Advisory Board (IPAB)
S. 1206, Medicare Prescription Drug Savings Act of 2011: Provisions related to Part D issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mike |
Anway |
|
|
|
Maya |
Bermingham |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Andrea |
Douglas |
|
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Gregory |
Gierer |
|
|
|
Ann |
Kaplan |
|
|
|
Kimberly |
Love |
|
|
|
Brian |
Nagle |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Matt |
Sulkala |
|
|
|
Jennifer |
Romans |
|
Health Policy Advisor - Sen. Bill Frist; Senior |
|
" |
" |
|
Health Policy Advisor - Sen. Jon Kyl |
|
Cara |
Moon |
|
Staff Asst. and Leg. Correspondent - Rep. John |
|
" |
" |
|
Shadegg; Leg. Asst. - Rep. Bobby Jindal; Senior |
|
" |
" |
|
Leg. Asst. and Leg. Director - Rep. Marsha |
|
" |
" |
|
Blackburn |
|
Hallie |
Maranchick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Korea Free Trade Agreement: Provisions related to intellectual property, market access and public health
Trans-Pacific Strategic Economic Partnership Agreement (TPP): Provisions related to intellectual property issues
Issues related to Special 301 and National Trade Estimate (NTE) submissions
Preference Programs
International market access and intellectual property issues
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Natl Security Council (NSC), Commerce - Dept of (DOC), U.S. Trade Representative (USTR), State - Dept of (DOS), Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Robert |
Filippone |
|
|
|
Lea |
Fisher |
|
|
|
Anne |
Pritchett |
|
|
|
Matt |
Sulkala |
|
|
|
Leo |
Farber |
|
Not applicable |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.phrma.org/about/member-companies
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |